Relating to cost-sharing requirements for breast examinations
SB430 would prohibit health insurance policies in West Virginia from imposing cost-sharing requirements, such as deductibles, copayments, or coinsurance, for covered screening, diagnostic, and supplemental breast examinations. The bill defines diagnostic breast examinations to include medically necessary breast MRI, ultrasound, or diagnostic mammography used to evaluate abnormalities found on screening or by other means, and defines supplemental breast examinations as medically necessary breast MRI or ultrasound used to screen higher-risk individuals when no abnormality is suspected.
The bill applies this no-cost-sharing requirement across multiple insurance frameworks in state law, including the Public Employees Insurance Act, accident and sickness insurance, group accident and sickness insurance, hospital and medical service corporations, health care corporations, and health maintenance organizations. It also allows the Insurance Commissioner to adopt rules to implement the measure, ties implementation to current professional guidelines such as those from the National Comprehensive Cancer Network, and delays application until coverage issued or renewed on or after specified effective dates in 2026. The bill also includes a federal tax-compatibility provision for high-deductible health plans and health savings accounts, preserving cost-sharing only to the extent needed to avoid HSA ineligibility under federal law.
The overall sentiment reflected in the bill materials is supportive and health-focused, with the stated purpose being to improve access to breast cancer-related imaging without out-of-pocket costs. No committee transcript or vote record is provided, so there is no recorded debate or formal vote history in the supplied materials. The bill’s structure and purpose suggest a consumer- and patient-protection approach aimed at reducing financial barriers to early detection and follow-up care.
Because no discussion transcripts are available, there are no documented points of contention from committee debate. The main policy tension inherent in the text is between expanding coverage without cost sharing and preserving compatibility with federal HSA-qualified high-deductible health plans; the bill addresses that issue directly by carving out an exception where necessary. Another potential area of concern for insurers is the mandate’s effect on benefit design and premium costs, though that concern is not expressly stated in the provided record.
SB430 would amend multiple chapters of West Virginia insurance law to require insurers and public employee health coverage to cover screening, diagnostic, and supplemental breast examinations without deductibles, copayments, coinsurance, or similar out-of-pocket costs, subject to a limited federal HSA/high-deductible plan exception. It would affect a broad range of carriers and health plans regulated under state law, including PEIA-related coverage, individual and group accident and sickness policies, hospital and medical service corporations, health care corporations, and HMOs. The bill also authorizes rulemaking by the Insurance Commissioner and would apply to coverage issued, renewed, or changed on or after the stated 2026 effective dates.
The bill appears to have a generally favorable, pro-access sentiment based on its stated purpose and the absence of recorded opposition in the provided materials. It is framed as a breast cancer coverage mandate intended to eliminate cost barriers for medically necessary imaging and screening. No committee testimony or vote history is included, so there is no evidence of formal support or opposition beyond the bill text itself.
No committee transcript or vote record was provided, so there are no documented points of contention from legislative debate. The principal policy issue visible in the text is the interaction with federal Health Savings Account rules for high-deductible health plans, which the bill addresses by allowing cost-sharing only to the extent needed to preserve HSA eligibility. A secondary, likely concern for insurers and plan administrators is the cost and administrative impact of mandating zero cost-sharing for additional breast imaging, but that concern is not explicitly recorded in the supplied materials.